New medicine for treatment of nephrotic syndrome in children

Oral methylprednisolone versus prednisolone: A pilot randomised control trial in treatment of first episode nephrotic syndrome in children, non-inferiority trial - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087429

Enrollment

Registered

2025-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes

Interventions

Intervention1: methylprednisolone: GROUP A will receive dose of methylprednisolone 1.6 mg/kg/day after food daily for 4 weeks (single doses/ OD) followed by 1.2 mg/kg/alternate day single dose afte

Eligibility

Inclusion criteria

Inclusion criteria: children between the ages of 4 and 14 years old with primary diagnosis of nephrotic syndrome first attack

Exclusion criteria

Exclusion criteria: children less than 4 years or more than 14 years, children having hypertension, hematuria, raised creatinine level or with secondary nephrotic syndrome due to any systemic disorder or drug

Design outcomes

Primary

Measure	Time frame
Comparative study of time taken to achieve remission from first episode of Nephrotic syndrome Between two drugsTimepoint: 4 weeks	—

Secondary

Measure	Time frame
Number of relapses during one year follow upTimepoint: one year	—

Countries

India

Contacts

Public ContactDr Subal Kumar Pradhan

SCB Medical college and Hospital

drsubal@rediffmail.com09777860915

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026